Trametinib and Dabrafenib Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	2
Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.	2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib